Skip to content

A head-to-head comparison of Percutaneous Mastoid Electrical Stimulator and Supraorbital Transcutaneous Stimulator in the prevention of migraine: A prospective, randomized controlled study

A head-to-head comparison of Percutaneous Mastoid Electrical Stimulator and Supraorbital Transcutaneous Stimulator in the prevention of migraine: A prospective, randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018257
Enrollment
Unknown
Registered
2018-09-07
Start date
2016-12-01
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

Group 2:supraorbital nerve stimulation, electrical cerebellar fastigial nucleus stimulation
Group 1:Bilateral posterior auricular mastoid stimulation

Sponsors

The Second People's Hospital of Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged 18-65 years; For migraine with or without aura, the diagnosis must be in accordance with the international classification of headache diseases, version 2 (ICHDd-3, 1.2.1 or 1.1); Age of first onset < 50 years; The disease duration is greater than or equal to 1 year; Frequency of attack is greater than 2 times/month; Volunteer and sign informed consent.

Exclusion criteria

Exclusion criteria: Received prophylactic medication for migraine in the past 3 months; Has used at least three prophylactic drugs; Drug abuse-related headaches (those who take painkiller > 10 days a month for a headache attack); Alcohol and/or other drug abusers; Persons undergoing hormone therapy; Serious neurological or mental illness; Patients with serious primary cardiovascular, cerebrovascular, liver, kidney and hematopoietic system diseases; Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
Severity of headache, nausea/vomiting, name/quantity of acute analgesic drugs, duration of headache;

Countries

China

Contacts

Public ContactJIan Wang

The Second People's Hospital of Chengdu

42523748@qq.com+86 18708198049

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026